In patients with STEMI undergoing PCI, dual antiplatelet therapy is used to prevent recurrent thrombotic events. The more potent platelet inhibitors increase the risk of bleeding, but the effectiveness of less potent inhibitors may vary according to the patient’s genotype. New research findings are summarized in a short video. https://nej.md/2N4IEAG See all Quick Take videos: http://nej.md/quick-take | The New England Journal of Medicine

Complete vs. Culprit-Only PCI in STEMI with Multivessel Disease What’s the optimal revascularization strategy in STEMI patients with multivessel coronary artery disease? Join Carlos Aguiar at cardiology This Week as he explores the latest trial insights and implications for interventional practice—only on #ESCTVToday https://ow.ly/UlcM50XwPnB #Cardiology #STEMI #PCI #ESC365 | European Society of Cardiology